Kevin Kunzmann

A protein targeted by some marketed lipid-lowering agents may increase risk of developing irritable bowel disease.

The first known dose-effect relationship study between colorectal neoplasia and smoking in patients with IBD strengthens the importance of achieving cessation.

Reports of a half-dozen confirmed cases of the rare vision-threatening condition has spurred conversation around the first-in-class geographic atrophy drug.

New cross-sectional data show the sex gap in alcohol-related mortality has been narrowing since 1999, as women have become more susceptible to alcohol use and related diseases.

New cohort analysis data provide more context into what factors influence the benefit of FMT in patients with recurrent CDI.

A study from China suggests calcium and magnesium malnutrition is associated with Crohn's disease inflammation and activity.

Vogel reviews the struggles behind adequately diagnosing long Covid and quantifying its impact of disease at this time of clinical research.

Skyrocketing rates of HCV have aligned with the opioid epidemic—and evidence the need for universal pregnancy screenings.

Though many countries established guidelines and strategies to eliminate the virus by 2030, the region is still behind on newborn virus management.

Lungcast's July episode guest discusses how long Covid therapy development is still about 5 years away from the market.

A meta-analysis suggest the correlation between PTH and non-alcoholic fatty liver disease is significant enough for it to be biomarker for disease.

A retrospective analysis shows the highly deadly condition has increased 7-fold among US women in the last 2 decades.

International data show conditions including cirrhosis and alcohol-associated liver disease significantly drive the likelihood of critical illness and death in COVID-19 patients.

In the latest Lungcast, a nationally-leading researcher and long COVID patient discusses what's known and unknown about the chronic viral syndrome.

Over 3 years, global health threats and national headlines have spurred medical schools to better address social and community-based determinants of health. What comes next?

An update to guidances prioritizes practices that complete RNA testing on all HCV antibody reactive samples in one step, for the sake of complete test rates.

A Lynchburg-based clinic was able to cure hepatitis C in all follow-through patients with substance abuse who underwent a comprehensive care plan over 8 weeks.

A study from Nepal showed a majority of teaching hospital health providers were accidentally exposed to needles. The group additionally had limited knowledge of their HBV vaccination status.

New data from the CONFIRM trial show the noninvasive FIT testing method is increasing in preference over colonoscopy by about 20% annually.

A meta-analysis shows patients with both NAFLD and type 2 diabetes are at significantly greater risk of hepatic decompensation and HCC over a 5-year span.

Direct-acting antivirals or interferon may improve the rate of overall or recurrence-free survival for patients with liver cancer.

A cross-sectional analysis from China suggests approximately 1 in 10 individuals suffer from incontinence, though not all are seeking adequate care or specialist consultation.

Early-stage data support KAN-101, a liver-targeting drug that's vying to become the first treatment approved to treat celiac disease.

A cascade-of-clearance study from the CDC shows the country is far from its goal of eliminating 80% of hepatitis C cases by 2030.

From a novel acne cream to a breakthrough depression drug, a half-dozen agent decisions are coming through in the coming 6 months.

Analysis of a novel form of the topical drug shows rosacea is benefitted within 2 weeks of daily administration.

An analysis of patients with psoriasis, PsA, or axSpA show risk of MACE with ixekizumab is consistently low.

The letter makes reference to an ongoing review of inspection findings from a third-party filler involved with the drug development. Regeneron will not require additional trial data.

Ritlecitinib becomes the second JAK inhibitor approved to treat alopecia—and the first to be indicated for patients aged 12 years and older.

Post hoc analysis of the topical therapy show patients receiving treatment for acne in the winter were as likely to achieve benefit as those receiving it in the summer.